HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Toxic Substances Act Vote Could Come Soon – Lautenberg

This article was originally published in The Rose Sheet

Executive Summary

Legislators, industry and others shared their views on updating the Toxic Substances Control Act at a Nov. 17 hearing of the Senate Environment and Public Works Committee’s Subcommittee on Superfund, Toxics and Environmental Health.

You may also be interested in...



In Brief

Under an amendment to the FDA Safety and Innovation Act, which passed the U.S. Senate May 24, there will be no further delays in implementation of FDA’s final rule for sunscreen testing and labeling. More news in brief.

Lautenberg Unveils TSCA Reform Bill, Putting Safety Burden-Of-Proof On Industry

Sen. Frank R. Lautenberg, D-N.J., introduced legislation April 14 updating the 35-year-old Toxic Substances Control Act to set the responsibility for chemical safety substantiation squarely on manufacturers’ shoulders.

TSCA Reform Needed, Stakeholders Agree, But Swift Passage Is Doubtful

Although Sen. Frank Lautenberg, D-N.J., is committed to recasting the Toxic Substances Control Act during the 112th Congress, speakers at the GlobalChem Conference in Baltimore were doubtful that it would pass soon.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel